Patient disposition
| Patient accounting . | Patients treated, n (%), N = 62 . |
|---|---|
| Ongoing | 12 (19) |
| Discontinued the study | 50 (81) |
| Primary reasons for discontinuation | |
| Disease progression | 15 (24) |
| Failure to achieve a response | 13 (21) |
| Adverse event | 7 (11) |
| Death | 4 (6) |
| Request of patient, primary investigator, sponsor, or regulatory agency | 4 (6) |
| Lost to follow-up | 1 (2) |
| Patient noncompliance | 1 (2) |
| Other* | 5 (8) |
| Patient accounting . | Patients treated, n (%), N = 62 . |
|---|---|
| Ongoing | 12 (19) |
| Discontinued the study | 50 (81) |
| Primary reasons for discontinuation | |
| Disease progression | 15 (24) |
| Failure to achieve a response | 13 (21) |
| Adverse event | 7 (11) |
| Death | 4 (6) |
| Request of patient, primary investigator, sponsor, or regulatory agency | 4 (6) |
| Lost to follow-up | 1 (2) |
| Patient noncompliance | 1 (2) |
| Other* | 5 (8) |
Includes allogeneic hematopoietic stem cell transplantation (n = 3), hematologic resistance (n = 1), and withdrawal of consent (n = 1).